{
    "id": 27309,
    "fullName": "EGFR T751_I759delinsN",
    "impact": "indel",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR T751_I759delinsN results in a deletion of nine amino acids in the protein kinase domain of the Egfr protein from aa 751 to aa 759, combined with the insertion of an asparagine (N) at the same site (UniProt.org). T751_I759delinsN has not been biochemically characterized, but is predicted to result in a gain of function based on the effect of other EGFR exon 19 deletion and deletion-insertion mutations (PMID: 19147750, PMID: 22190593, PMID: 23387505).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 439,
                    "pubMedId": 22190593,
                    "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22190593"
                },
                {
                    "id": 1890,
                    "pubMedId": 19147750,
                    "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19147750"
                },
                {
                    "id": 441,
                    "pubMedId": 23387505,
                    "title": "Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23387505"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "T751_I759delinsN",
    "createDate": "11/28/2017",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 135935,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174788_55174814delinsAAC",
        "cDna": "c.2251_2277delinsAAC",
        "protein": "p.T751_I759delinsN",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14707,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28732,
                "profileName": "EGFR T751_I759delinsN"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14708,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28732,
                "profileName": "EGFR T751_I759delinsN"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14709,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28732,
                "profileName": "EGFR T751_I759delinsN"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14713,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28732,
                "profileName": "EGFR T751_I759delinsN"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20112,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment resulted in progressive disease with a progression-free survival of 2 months in a patient with non-small cell lung cancer harboring EGFR T751_I759delinsN (PMID: 31715539).",
            "molecularProfile": {
                "id": 28732,
                "profileName": "EGFR T751_I759delinsN"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17697,
                    "pubMedId": 31715539,
                    "title": "Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31715539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14717,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 28732,
                "profileName": "EGFR T751_I759delinsN"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14715,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28732,
                "profileName": "EGFR T751_I759delinsN"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28732,
            "profileName": "EGFR T751_I759delinsN",
            "profileTreatmentApproaches": [
                {
                    "id": 16642,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR T751_I759delinsN"
                },
                {
                    "id": 16643,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR T751_I759delinsN"
                },
                {
                    "id": 16641,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR T751_I759delinsN"
                },
                {
                    "id": 16644,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR T751_I759delinsN"
                },
                {
                    "id": 16645,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR T751_I759delinsN"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135935,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174788_55174814delinsAAC",
            "cDna": "c.2251_2277delinsAAC",
            "protein": "p.T751_I759delinsN",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}